InvestSMART

Cynata Therapeutics Limited (ASX: CYP) - Announcements

- Current share price for CYP : $0.011

ASX company news and announcements for Cynata Therapeutics Limited (CYP) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Cynata Therapeutics Limited (CYP) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Cynata Therapeutics Limited (CYP), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Cynata Therapeutics Limited (CYP)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$3 Appendix 3B-Exercise of Options 28 Feb 2018 5:53PM $1.155 $0.011 fallen by 99.05%
$3 Response to ASX Aware Query 28 Feb 2018 1:33PM $1.145 $0.011 fallen by 99.04%
$3 Appendix 4D & Half-Year Financial Statements 27 Feb 2018 5:47PM $1.135 $0.011 fallen by 99.03%
$3 Excellent Data from Final Preliminary Evaluation Period 27 Feb 2018 10:21AM $1.145 $0.011 fallen by 99.04%
$3 Cynata Engineered MSC Study Review Reveals Promising Results 5 Feb 2018 9:22AM $0.880 $0.011 fallen by 98.75%
$3 December 2017 Quarterly Report 30 Jan 2018 5:03PM $0.900 $0.011 fallen by 98.78%
$3 Cynata Treats First Patient in Cohort B 24 Jan 2018 9:38AM $0.670 $0.011 fallen by 98.36%
$3 Cyanta & Celularity Inc Execute MOU 23 Jan 2018 9:59AM $0.640 $0.011 fallen by 98.28%
$3 Lapse of Unlisted Options 23 Jan 2018 9:42AM $0.640 $0.011 fallen by 98.28%
$3 Encouraging Early Data-Cynata Clinical Trial Proceeds 22 Jan 2018 12:17PM $0.590 $0.011 fallen by 98.14%
$3 Trading Halt 22 Jan 2018 9:33AM $0.590 $0.011 fallen by 98.14%
$3 Release of Securities from Voluntary Escrow 11 Jan 2018 7:08PM $0.585 $0.011 fallen by 98.12%
$3 Interview with Cynata Co-Founder Professor Slukvin 11 Jan 2018 12:04PM $0.585 $0.011 fallen by 98.12%
$3 End of Year Newsletter & 2018 Outlook 18 Dec 2017 9:52AM $0.595 $0.011 fallen by 98.15%
$3 Cynata Receives $1.3m R&D Tax Incentive Refund 14 Dec 2017 11:39AM $0.595 $0.011 fallen by 98.15%
$3 Final Preclinical Asthma Study Confirms Efficacy 11 Dec 2017 5:11PM $0.595 $0.011 fallen by 98.15%
$3 United States Patent Allowance for Core Cynata Technology 7 Dec 2017 2:24PM $0.620 $0.011 fallen by 98.23%
$3 Appendix 3Y-Paul Wotton 20 Nov 2017 8:23AM $0.605 $0.011 fallen by 98.18%
$3 Appendix 3B 20 Nov 2017 8:23AM $0.605 $0.011 fallen by 98.18%
$3 Results of Annual General Meeting 17 Nov 2017 10:17AM $0.610 $0.011 fallen by 98.20%
$3 Managing Director's Annual General Meeting Presentation 17 Nov 2017 8:41AM $0.650 $0.011 fallen by 98.31%
$3 Chairman's Annual General Meeting Address 17 Nov 2017 8:40AM $0.650 $0.011 fallen by 98.31%
$3 Company Investor Presentation 15 Nov 2017 10:08AM $0.655 $0.011 fallen by 98.32%
$3 Enrolment Completed in 1st Cohort of Cynata Clinical Trial 15 Nov 2017 9:08AM $0.645 $0.011 fallen by 98.29%
$3 September 2017 Quarterly Report 27 Oct 2017 6:45PM $0.620 $0.011 fallen by 98.23%

526 - 550 of 699 results

Page 22 of 28

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.